Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials
Objective. We performed a systematic review of the literature to evaluate the effects of alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes mellitus. Research design and methods. The databases MEDLINE and EMBASE were searched using the key words “lipoic acid’’, “thioc...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2012/456279 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850208869942296576 |
|---|---|
| author | Gerritje S. Mijnhout Boudewijn J. Kollen Alaa Alkhalaf Nanno Kleefstra Henk J. G. Bilo |
| author_facet | Gerritje S. Mijnhout Boudewijn J. Kollen Alaa Alkhalaf Nanno Kleefstra Henk J. G. Bilo |
| author_sort | Gerritje S. Mijnhout |
| collection | DOAJ |
| description | Objective. We performed a systematic review of the literature to evaluate the effects of alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes mellitus. Research design and methods. The databases MEDLINE and EMBASE were searched using the key words “lipoic acid’’, “thioctic acid’’, “diabet*’’, and the MeSH-terms “thioctic acid’’ and “diabetes mellitus’’. Randomised controlled trials using the TSS score as the outcome measure were selected and assessed for their methodological quality. Study selection and quality assessment were performed independently by three observers. Results. Overall, the pooled standardized mean difference estimated from all trials revealed a reduction in TSS scores of −2.26 (CI: −3.12 to −1.41; P=0.00001) in favour of alpha lipoic acid administration. Subgroup analyses of oral administration (−1.78 CI: −2.45 to −1.10; P=0.00001) and intravenous administration (−2.81 CI: −4.16 to −1.46; P=0.0001) confirmed the robustness of the overall result. Conclusions. When given intravenously at a dosage of 600 mg/day over a period of 3 weeks, alpha lipoic acid leads to a significant and clinically relevant reduction in neuropathic pain (grade of recommendation A). It is unclear if the significant improvements seen after 3–5 weeks of oral administration at a dosage of >600 mg/day are clinically relevant. |
| format | Article |
| id | doaj-art-981ba3dc19fe4e0595148621f24df27a |
| institution | OA Journals |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-981ba3dc19fe4e0595148621f24df27a2025-08-20T02:10:09ZengWileyInternational Journal of Endocrinology1687-83371687-83452012-01-01201210.1155/2012/456279456279Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled TrialsGerritje S. Mijnhout0Boudewijn J. Kollen1Alaa Alkhalaf2Nanno Kleefstra3Henk J. G. Bilo4Department of Internal Medicine, Isala Clinics, P.O. Box 10400, 8000 GK Zwolle, The NetherlandsDepartment of General Practice, University Medical Centre Groningen, University of Groningen, P.O. Box 30001, 9700 RB Groningen, The NetherlandsDepartment of Internal Medicine, Isala Clinics, P.O. Box 10400, 8000 GK Zwolle, The NetherlandsDepartment of Internal Medicine, University Medical Centre Groningen, University of Groningen, P.O. Box 30001, 9700 RB Groningen, The NetherlandsDepartment of Internal Medicine, Isala Clinics, P.O. Box 10400, 8000 GK Zwolle, The NetherlandsObjective. We performed a systematic review of the literature to evaluate the effects of alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes mellitus. Research design and methods. The databases MEDLINE and EMBASE were searched using the key words “lipoic acid’’, “thioctic acid’’, “diabet*’’, and the MeSH-terms “thioctic acid’’ and “diabetes mellitus’’. Randomised controlled trials using the TSS score as the outcome measure were selected and assessed for their methodological quality. Study selection and quality assessment were performed independently by three observers. Results. Overall, the pooled standardized mean difference estimated from all trials revealed a reduction in TSS scores of −2.26 (CI: −3.12 to −1.41; P=0.00001) in favour of alpha lipoic acid administration. Subgroup analyses of oral administration (−1.78 CI: −2.45 to −1.10; P=0.00001) and intravenous administration (−2.81 CI: −4.16 to −1.46; P=0.0001) confirmed the robustness of the overall result. Conclusions. When given intravenously at a dosage of 600 mg/day over a period of 3 weeks, alpha lipoic acid leads to a significant and clinically relevant reduction in neuropathic pain (grade of recommendation A). It is unclear if the significant improvements seen after 3–5 weeks of oral administration at a dosage of >600 mg/day are clinically relevant.http://dx.doi.org/10.1155/2012/456279 |
| spellingShingle | Gerritje S. Mijnhout Boudewijn J. Kollen Alaa Alkhalaf Nanno Kleefstra Henk J. G. Bilo Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials International Journal of Endocrinology |
| title | Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials |
| title_full | Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials |
| title_fullStr | Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials |
| title_full_unstemmed | Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials |
| title_short | Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials |
| title_sort | alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes a meta analysis of randomized controlled trials |
| url | http://dx.doi.org/10.1155/2012/456279 |
| work_keys_str_mv | AT gerritjesmijnhout alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials AT boudewijnjkollen alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials AT alaaalkhalaf alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials AT nannokleefstra alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials AT henkjgbilo alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials |